Table 1.
Patient characteristics according to the response at 6 months treatment of TNF inhibitors.
| Characteristics, n (%) | Remission (n = 29) | No remission (n = 69) | p-value |
|---|---|---|---|
| Sex | 0.059 | ||
| Male | 9 (31.0) | 10 (14.5) | |
| Female | 20 (69.0) | 59 (85.5) | |
| Age | 51.4 ± 13.4 | 53.6 ± 13.9 | 0.399 |
| < 65 | 26 (89.7) | 53 (76.8) | 0.142 |
| ≥ 65 | 3 (10.3) | 16 (23.2) | |
| BMI, kg/m2 | 23.4 ± 3.0 | 22.3 ± 3.8 | 0.220 |
| < 23 | 13 (44.8) | 42 (60.9) | 0.144 |
| ≥ 23 | 16 (55.2) | 27 (39.1) | |
| Duration of rheumatoid arthritis, months | 103.9 ± 87.8 | 111.0 ± 69.2 | 0.666 |
| Rheumatoid factor | 0.329 | ||
| Positive | 20 (69.0) | 54 (78.3) | |
| Negative | 9 (31.0) | 15 (21.7) | |
| ACPA | 0.177 | ||
| Positive | 17 (34.6) | 49 (79.0) | |
| Negative | 9 (65.4) | 13 (21.0) | |
| Concomitant drug | |||
| Hydroxychloroquine | 0.902 | ||
| Yes | 16 (55.2) | 39 (56.5) | |
| No | 13 (44.8) | 30 (43.5) | |
| Leflunomide | 0.665 | ||
| Yes | 10 (34.5) | 27 (39.1) | |
| No | 19 (65.5) | 42 (60.9) | |
| Methotrexate | 0.319 | ||
| Yes | 19 (65.5) | 52 (75.4) | |
| No | 10 (34.5) | 17 (24.6) | |
| Sulfasalazine | 0.111 | ||
| Yes | 7 (24.1) | 7 (10.1) | |
| No | 22 (75.9) | 62 (89.9) | |
| Tacrolimus | 0.986 | ||
| Yes | 5 (17.2) | 12 (17.4) | |
| No | 24 (82.8) | 57 (82.6) | |
| Comorbidity | |||
| Diabetes | 0.669 | ||
| Yes | 1 (3.6) | 5 (7.2) | |
| No | 27 (96.4) | 64 (92.8) | |
| Dyslipidemia | 1.000 | ||
| Yes | 3 (10.7) | 9 (13.0) | |
| No | 25 (89.3) | 60 (87.0) | |
| Hypertension | 0.060 | ||
| Yes | 1 (3.6) | 14 (20.3) | |
| No | 27 (96.4) | 55 (79.7) | |
| Osteoporosis | 0.725 | ||
| Yes | 4 (14.3) | 7 (10.1) | |
| No | 24 (85.7) | 62 (89.9) | |
| Vitamin D deficiency | 0.272 | ||
| Yes | 1 (3.6) | 9 (13.0) | |
| No | 27 (96.4) | 60 (87.0) | |
| Baseline DAS28 with its subcomponents | |||
| DAS28 | 5.8 ± 1.2 | 5.8 ± 1.1 | 0.696 |
| Tender joint count 28 | 9.6 ± 8.3 | 10.7 ± 74.3 | 0.782 |
| Swollen joint count 28 | 6.6 ± 7.1 | 7.5 ± 5.7 | 0.872 |
| Global health | 55.3 ± 18.5 | 62.4 ± 20.2 | 0.167 |
| ESR | 54.7 ± 29.5 | 49.5 ± 27.3 | 0.379 |
| CRP | 3.0 ± 4.4 | 2.1 ± 2.5 | 0.113 |
BMI: body mass index; ACPA: anticyclic citrullinated peptide antibody; DAS28: disease activity score 28 joints; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein.